eglumegad

Eglumegad is a highly effective and selective agonist of group II (mGlu2/3) receptor (IC50s: 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively).

Eglumetad (also known as LY354740) is an investigational compound developed by Eli Lilly and Company, currently under research for the treatment of anxiety disorders and substance addiction. This compound originates from glutamate, demonstrating a novel mechanism of action.

Eglumegad (LY354740) hydrochloride is a potent, selective agonist for group II (mGlu2 3) receptors, showing IC50 values of 5 nM for mGlu2 and 24 nM for mGlu3 receptors in transfected human cells. This compound provides neuroprotection against NMDA-induced toxicity and exhibits anxiolytic- and antipsychotic-like properties [1].

Talaglumetad hydrochloride is a prodrug of Eglumegad which is the potent and selective agonist of the type II metabotropic glutamate receptor (mGluR2 3) to treat with psychiatric disorders.